Baar Joseph
Case Western Reserve University, Ireland Cancer Center, 11100 Euclid Avenue, Cleveland, OH 44011, USA.
Curr Opin Investig Drugs. 2007 Dec;8(12):987-95.
Advances have been made in breast cancer therapy, in both the adjuvant and metastatic settings. For example, in the adjuvant setting, genomic studies of breast cancer tissues have identified women with estrogen receptor-positive tumors who might not require chemotherapy, leading to the development of a diagnostic tool. There have also been significant developments with anticancer agents that target tumor cell surface receptors, such as HER2/neu, and those involved in angiogenesis and kinase-dependent pathways. New areas of research focus on the concept of breast cancer stem cells as well as the prognostic importance of bone marrow micrometastases in early-stage breast cancer. This review summarizes these advances in breast cancer clinical research.
乳腺癌治疗在辅助治疗和转移性治疗方面均取得了进展。例如，在辅助治疗方面，对乳腺癌组织的基因组研究已识别出雌激素受体阳性肿瘤的女性患者可能无需化疗，从而促成了一种诊断工具的开发。针对肿瘤细胞表面受体（如HER2/neu）以及参与血管生成和激酶依赖性途径的抗癌药物也有了重大进展。新的研究领域聚焦于乳腺癌干细胞的概念以及早期乳腺癌中骨髓微转移的预后重要性。本综述总结了乳腺癌临床研究中的这些进展。
